Gilead Sciences said it has designated Yonsei Cancer Center as a Gilead HOPE (Hematology-Oncology Portfolio Engagement Site) institution and announced signing a memorandum of understanding (MoU) for collaborative research and development of innovative cancer therapeutics.
Both organizations plan to work together on cancer drug clinical trials within Korea through this agreement.
Gilead is expanding its oncology pipeline and global development and clinical approvals in Korea.
This includes partnerships formed with Seoul National University Hospital and Samsung Medical Center last December, establishing an organic cooperation system with three Korean clinical centers.
The company aims to contribute to the enhancement of Korean cancer drug research and development capabilities and to improve access to innovative treatments for cancer patients through this collaboration with globally recognized researchers.
"Through the expansion of strategic partnerships with world-renowned domestic clinical trial centers, we hope that Gilead's innovative cancer drugs will contribute to the health improvement of more cancer patients in Korea and to the enhancement of public health," Gilead Sciences Korea General Manager Choi Jae-yeon said. "In connection with the Ministry of Health and Welfare's emphasis on the importance of international joint research and development, Gilead Sciences Korea will strive to attract more research and development opportunities to enhance the domestic drug development capacity."
Yonsei Cancer Center Director Choi Jin-seop also said, "Yonsei Cancer Center prioritizes patient satisfaction and strives to provide patients with world-class experiences in various fields."
The hospital expects this agreement with Gilead, a leader in oncology innovation, to create significant synergies in developing new cancer drugs, combining Gilead's research capabilities and know-how with the capacity of Korean researchers, Choi added.
Choi went on to say that this partnership will provide patients with opportunities to participate in various global clinical trials, playing a crucial role in addressing unmet medical needs.
Meanwhile, Gilead Sciences aims to provide treatment benefits to more than 500,000 cancer patients globally by 2030, including treatment of various types of cancer, including breast, lung, and bladder cancer.
The company is conducting numerous clinical programs for major cancer types both domestically and internationally.